Clinical and pharmacological group: & nbsp

Other Metabolites

Included in the formulation
  • Angiocarcinoma
    solution for injections 
  • Vazomag
    solution for injections 
    Olainfarm, AO     Latvia
  • Idrinol®
    solution in / in d / eye 
  • Idrinol®
    capsules inwards 
    Olainfarm, AO     Latvia
  • Cardionate®
    solution for injections 
    NIZHFARM, JSC     Russia
  • Cardionate®
    capsules inwards 
    NIZHFARM, JSC     Russia
  • Cardionate®
    capsules inwards 
    MAKIZ-PHARMA, LLC     Russia
  • Meldoney
    solution in / in d / eye w / m 
    ELLARA, LTD.     Russia
  • Meldoney
    capsules inwards 
  • Meldoney
    solution for injections 
    BIOCHEMIST, OJSC     Russia
  • Meldoney
    solution for injections 
  • Meldoney
    solution for injections 
    ATOLL, LLC     Russia
  • Meldoney
    solution for injections 
    BIOSINTEZ, PAO     Russia
  • Meldonius Organica
    solution for injections 
    ORGANICS, JSC     Russia
  • Meldonium-Binergia
    solution in / in d / eye 
    BINERGIYA, CJSC     Russia
  • Meldonij DECO
    solution for injections 
    Company DEKO, LLC     Russia
  • Meldonius-SOLOFARM
    solution for injections 
    GROTEKS, LLC     Russia
  • Meldonius-Eskom
    solution for injections 
    ESKOM NPK, OAO     Russia
  • Melfor®
    solution for injections 
    AVISTA, LLC     Russia
  • Melfor®
    capsules inwards 
       
  • MILDRONATE®
    capsules inwards 
    GRINDEX, JSC     Latvia
  • MILDRONATE®
    capsules inwards 
    GRINDEX, JSC     Latvia
  • MILDRONATE®
    solution w / m in / in d / eye 
    GRINDEX, JSC     Latvia
  • Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):

    VED

    ONLS

    АТХ:

    C.01.E.B.22   Meldoney

    C.01.E.B   Other drugs for the treatment of heart disease

    Pharmacodynamics:

    The drug has a metabolic, antianginal, cardioprotective, antihypoxic, adaptogenic effect and improves cerebral circulation.

    Stimulates metabolic processes, with acute myocardial infarction slows tissue necrosis, shortens the rehabilitation period. With heart failure improves myocardial contractility and increases exercise tolerance. In acute and chronic disorders of cerebral circulation improves blood circulation in the source of ischemia. Increases immunity, eliminates the syndrome of withdrawal from chronic alcoholism. Increases working capacity and endurance, reduces symptoms of mental and physical overstrain.

    Pharmacokinetics:

    When ingested well absorbed from gastrointestinal tract, and biodoparity is about 78%. Maximum concentration in the blood in 1-2 hours. Biotransformed in the body with the formation of two major metabolites, which are excreted by the kidneys. The half-life is 3-6 hours.

    Indications:

    - reduced working capacity;

    - Physical overstrain, including in athletes;

    - Postoperative period to accelerate rehabilitation;

    - ischemic heart disease: angina pectoris, myocardial infarction;

    - chronic heart failure;

    - pain in the heart against the background of dyshormonal myocardial dystrophy;

    - abstinent alcohol syndrome;

    - disorders of blood supply to the brain (stroke, cerebrovascular insufficiency);

    - acute disturbance of blood circulation in the retina, hemophthalmia and hemorrhage into the retina of various etiologies;

    - thrombosis of the central vein of the retina and its branches, retinopathy of various etiologies (including diabetic and hypertensive) - only for parabulbar injection.

    VII.H30-H36.H34.8   Other retinal vascular occlusions

    VI.G40-G47.G46 *   Vascular cerebral syndromes in cerebrovascular diseases (I60-I67 +)

    VII.H30-H36.H35.0   Background retinopathy and retinal vascular changes

    VII.H30-H36.H35.6   Retinal hemorrhage

    VII.H30-H36.H36.0 *   Diabetic retinopathy (E10-E14 + with common fourth sign .3)

    VII.H43-H45.H44.8   Other diseases of the eyeball

    IX.I20-I25.I21   Acute myocardial infarction

    IX.I30-I52.I50.0   Congestive heart failure

    IX.I60-I69.I64   Stroke not specified as a hemorrhage or infarction

    XVIII.R00-R09.R07.2   Pain in the region of the heart

    IX.I20-I25.I20   Angina pectoris [angina pectoris]

    Contraindications:

    Individual intolerance.

    Increase in intracranial pressure (with violation of venous outflow and intracranial tumors).

    Pregnancy and the period of breastfeeding.

    Carefully:No data.
    Pregnancy and lactation:

    Action category for the fetus by FDA - С. The drug is prohibited for use during pregnancy and breastfeeding.

    Dosing and Administration:

    The drug is injected inside, intravenously and intramuscularly, parabulbar, dosage, multiplicity of administration and duration of the course of treatment are selected individually.

    Average doses for adults: ingestion - 250 mg 2-4 times a day, parenterally - 500 mg per day dayki, parabulbar - 50 mg in day.

    Side effects:

    Digestive system: dyspepsia.

    Nervous system: excitation.

    The cardiovascular system: tachycardia, arterial hypotension.

    Leather: itching.

    Overdose:

    When an overdose develops irritation, insomnia, nausea, vomiting, convulsions, respiratory failure, coma, arterial hypotension, cardiac arrest. Treatment symptomatic.

    Interaction:

    Application simultaneously with nitroglycerin, nifedipine, alpha-adrenoblockers and other antihypertensive agents and peripheral vasodilators is possible only according to the doctor's prescription with great care. Compatible with anticoagulants and antiplatelet agents, antianginal drugs, antiarrhythmics, bronchodilators, diuretics.

    Special instructions:

    Athletes are appointed according to special schemes in conjunction with other means.

    Instructions
    Up